Nadine Andrieu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1830656/publications.pdf

Version: 2024-02-01

			471061	4	433756	
ı	30	3,174	17		31	
ı	papers	citations	h-index		g-index	
ı						
	33	33	33		5184	
	all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial Cancer, 2022, 21, 211-227.	0.9	10
2	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. Journal of the National Cancer Institute, 2022, 114, 540-552.	3.0	7
3	Gene―and pathwayâ€level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility. International Journal of Cancer, 2021, 148, 1895-1909.	2.3	5
4	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5 . 8	19
5	Boosting GWAS using biological networks: A study on susceptibility to familial breast cancer. PLoS Computational Biology, 2021, 17, e1008819.	1.5	4
6	A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers. BMC Medical Research Methodology, 2021, 21, 155.	1.4	3
7	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	0.7	34
8	Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation. Breast Cancer Research, 2021, 23, 79.	2.2	3
9	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
10	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	2.2	41
11	Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144, 1962-1974.	2.3	50
12	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Research, 2018, 20, 28.	2.2	35
13	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	1.4	21
14	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	1.4	33
15	GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, 490.	1.3	14
16	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
17	Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families. Carcinogenesis, 2017, 38, 994-1003.	1.3	17
18	GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer, 2016, 16, 13.	1.1	13

#	Article	IF	CITATIONS
19	Mutation screening of MIR146A/B and BRCA1/2 3′-UTRs in the GENESIS study. European Journal of Human Genetics, 2016, 24, 1324-1329.	1.4	8
20	Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. PLoS ONE, 2015, 10, e0136192.	1.1	11
21	Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in <i>BRCA1/2</i> Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 698-707.	1.1	21
22	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
23	Mutation analysis of PALB2 gene in French breast cancer families. Breast Cancer Research and Treatment, 2015, 154, 463-471.	1.1	17
24	Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660.	3.0	186
25	Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Research and Treatment, 2011, 130, 927-938.	1.1	46
26	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	1.1	63
27	Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. Journal of Clinical Oncology, 2006, 24, 3361-3366.	0.8	188
28	A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genetic Epidemiology, 2005, 29, 1-11.	0.6	136
29	Ataxia-Telangiectasia genes and breast cancer risk in a French family study. Journal of Dairy Research, 2005, 72, 73-80.	0.7	12
30	Cancer risk in heterozygotes for ataxia-telangiectasia. International Journal of Cancer, 2001, 93, 288-293.	2.3	124